CLINICAL OUTCOMES TurboHawk Peripheral Plaque Excision System
The DEFINITIVE LE study is one of the largest multinational, multicenter PAD device studies to date, enrolling 800 patients from 47 sites in the United States and Europe. It provides insight into the clinical utility of directional atherectomy with the TurboHawk™ and SilverHawk™ directional atherectomy devices in a broad range of patients, including diabetics, non-diabetics, claudicants, and those with critical limb ischemia (CLI).
Read more about the DEFINITIVE LE clinical study in published, peer-reviewed journals:
Download these clinical paper reviews and learn more about DEFINITIVE LE results overall.